Heron Therapeutics Inc
NASDAQ:HRTX
Heron Therapeutics Inc
NASDAQ:HRTX
Price:
2.77 USD
-6.42%
Market Closed
Updated:
May 13, 2024
Section:
Relative Value
The Relative Value of one
HRTX
stock under the Base Case scenario is
5.64
USD.
Compared to the current market price of 2.77 USD,
Heron Therapeutics Inc
is
Undervalued by 51%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HRTX
Relative Value
Base Case
5.64
USD
Undervaluation 51%
Valuation Multiples
Multiples Across Competitors
HRTX Competitors Multiples
Heron Therapeutics Inc Competitors
Heron Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Heron Therapeutics Inc
NASDAQ:HRTX
|
416.5m USD | 3.2 | -5.1 | -6.2 | -6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.4B USD | 5.6 | 44.2 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.9B USD | 11 | 30.1 | 24.2 | 25.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.3B USD | 8.2 | 27.8 | 22.5 | 24.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.9B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 169.8 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
44.9B USD | 8.7 | -7.5 | -8.1 | -7.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.3B USD | 3.3 | 27.6 | 14.1 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.6 | 45.6 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
